The first cases of Angelman Syndrome (AS) were reported in 1965 by the English pediatrician Herry Angelman, who described his patients as ''Puppet Children'' because of ''their flat heads, jerky movements, protruding tongues and bouts of laughter give them a superficial resemblance to puppets, an unscientific name but one which may provide for easy identification'' (Angelman, 1965) . Since that original study more than 50 years ago, AS symptomatology has been elucidated and the etiology of the disorder identified.
A variety of genetic abnormalities involving chromosome 15q11-13 are responsible for AS. In the vast majority of patients with a clinical diagnosis of AS, the genetic abnormalities result in the silencing of UBE3A, which is localized in the 15q11-13 region and is inherited from the mother (Chamberlain and Lalande, 2010) . Indeed, in neurons, UBE3A is imprinted such that the paternal UBE3A allele is normally silenced and the maternal allele is expressed. Thus, in AS, the maternal UBE3A allele is either absent or inactivated, resulting in no active copies of the gene. UBE3A encodes for the E3A ubiquitin ligase, whose role is to conjugate ubiquitin groups to selective sets of substrate proteins, thereby targeting them for degradation through the ubiquitin-proteasome system (Chamberlain and Lalande, 2010) .
The evolutionarily conserved imprinting of UBE3A has been exploited to genetically engineer mice (Ube3a mÀ/p+ ) (Jiang et al., 1998; Miura et al., 2002) in which the maternal Ube3a allele is deleted throughout the brain (Dindot et al., 2007) and results in phenotypes consistent with AS (Jiang et al., 1998; Miura et al., 2002) . The maternal Ube3a-null mouse model of AS has been critical for demonstrating that the absence of Ube3a is sufficient to produce a number of AS-associated pathophysiologies (see below). However, it is possible that other genes affected by chromosome 15q11-13 deletions, which are the most common and severe in patients, are involved in AS symptomatology. Clinical features of AS patients successfully modeled in Ube3a mÀ/p+ mice include cognitive impairments, speech impairments, seizures, electroencephalographic (EEG) abnormalities, hyperactivity, and movement/balance problems (Jiang et al., 1998; Miura et al., 2002) . Notably, up to 90% of AS patients experience generalized epilepsy syndrome characterized by atypical absent, myoclonic, tonic-clonic, and atonic seizures.
Epilepsy is a debilitating symptom for AS patients and their caregivers, especially since the recurrent and severe seizures are refractory to treatment with anticonvulsant drugs (Thibert et al., 2013) .
Although the precise pathological mechanism underlying epileptogenesis in AS is not clear, it is believed that the imbalance between local excitatoryinhibitory circuits results in generalized cortical and/or subcortical hyperexcitability. Accordingly, previous studies have demonstrated that the maternal deletion of Ube3a results in aberrant excitatory synapses, decreased excitatory drive, and reduced spine density that leads to impaired synaptic plasticity and the disruption of synaptic connectivity (Yashiro et al., 2009). Moreover, maternal Ube3a deletion also affects inhibitory GABAergic neurotransmission as demonstrated by the reduction of GABAergic input onto layer (L) 2/3 pyramidal neurons of the visual cortex (Wallace et al., 2012) .
In this issue of Neuron, Judson and colleagues identify GABAergic cortical neurons as being responsible for the pathogenesis of circuit hyperexcitability in AS and provide compelling evidence that causally implicate selective deletion of Ube3a in GABAergic neurons in the epileptogenesis and EEG abnormalities reported in AS model mice. The authors employ novel mouse models to selectively delete maternal Ube3a in either GABAergic or glutamatergic neurons in L2/3 of the visual cortex (Judson et al., 2016) . The idea that Ube3a deletion generates neuron-specific abnormalities builds upon previous findings from the same group indicating that the Ube3a mÀ/p+ mice (where Ube3a is deleted in both glutamatergic and GABAergic neurons) display presynaptic defects at GABAergic inhibitory synapses, resulting in fewer functional synapses (Figure 1 ) (Wallace et al., 2012 ::Gad2-Cre mice displayed increased seizure susceptibility induced either with the GABA A R antagonist flurothyl or with a loud sound ($125 dB; audiogenic seizure). Finally, these mice displayed EEG abnormalities and the accumulation of clathrin-coated vesicles (CCVs) at GABAergic and glutamatergic presynaptic terminals (Figure 1) (Judson et al., 2016) , consistent with the phenotype observed in Ube3a mÀ/p+ mice ( Figure 1) (Wallace et al., 2012) . Thus, selective deletion of Ube3a in GABAergic neurons enhances seizure susceptibility and severity and leads to AS-like EEG abnormalities and aberrant L2/3 presynaptic accumulation of CCVs without inducing any of the GABAergic synaptic deficits observed in mice with maternal deletion of Ube3a in nearly all neurons.
These unexpected results suggest that the circuit hyperexcitability observed in AS is not correlated with GABAergic synaptic deficits and impaired synaptic inhibition onto L2/3 pyramidal neurons. However, one cannot exclude the possibility that the deletion of Ube3a in GABAergic neurons has broader effects outside of the cortical circuit studied by Judson and colleagues that could potentially link GABAergic synaptic deficits to the increased seizure susceptibility and the abnormal EEG. Indeed, GABAergic inhibition has long been considered as the main brake in neuronal networks that prevents the generation and spread of seizure activity. Moreover, many of the anticonvulsant drugs used in the clinic act by enhancing GABAergic inhibition. These drugs include positive allosteric modulators of GABA A receptors, benzodiazepines and barbiturates, and drugs that inhibit GABA uptake (tiagabine) and degradation (vigabatrin) (Khazipov, 2016) . In the future, it will be of interest to identify the brain circuits involved in the generation of epilepsy and EEG abnormalities in AS mice. GABAergic circuits in the thalamus and the basal ganglia are involved in epileptogenesis (Huguenard and McCormick, 2007; Rektor et al., 2012) and could be potential brain regions of interest for future investigations.
Judson and colleagues also asked whether selective deletion of maternal Ube3a in glutamatergic neurons is sufficient to generate synaptic and behavioral phenotypes. To answer this question, the authors crossed a conditional mouse line where the maternal Ube3a allele is interrupted by the insertion of a floxed STOP cassette (Ube3a
STOP/p+
) with the Gad2-Cre line, generating mice in which the selective expression of Cre recombinase in GABAergic neurons excises the STOP cassette and allows for the expression of the maternal Ube3a. Thus, the maternal Ube3a allele is deleted selectively in glutamatergic neurons in the Ube3a STOP/p+ ::Gad2-Cre mice, which constitutes simultaneously a model for the reinstatement of Ube3a into GABAergic neurons. When synaptic function in the Ube3a STOP/p+ ::Gad2-Cre mice was examined, the authors found that the ability of L2/3 pyramidal neurons to respond to evoked, but not spontaneous, GABAergic transmission was reduced, suggesting that GABA A receptor function was likely intact. Moreover, by performing an elegant series of synaptic physiology experiments, the authors concluded that this effect was caused by cell-autonomous Ube3a loss in glutamatergic neurons (Figure 1 ) (Judson et al., 2016) . The reduced sensitivity of pyramidal neurons to GABAergic inhibition can be explained by changes in tonic inhibition, exerted by extrasynaptic GABA A R, which specifically contain the delta subunit (d-GABA A R). Tonic inhibition is considered to be an important component of the computational mechanisms that modulate neuronal excitability and generate rhythmic activity and neuronal oscillations. Thus, reduced sensitivity to tonic GABAergic inhibition could result in altered network excitability. Judson and colleagues tested this hypothesis by treating cortical slices with gabazine to antagonize synaptic GABA A Rs and THIP (gaboxadol) to stimulate extrasynaptic d-GABA A Rs and record currents sensitive to these pharmacological treatments. They found a reduction in THIP/gabazine-sensitive tonic currents in pyramidal neurons with maternal Ube3a deletion (Figure 1) (Judson et al., 2016) . Overall, these results demonstrate that the absence of Ube3a in glutamatergic neurons impairs the sensitivity of these neurons to tonic GABAergic inhibition in a cell-autonomous manner.
An alternative explanation for the reduced sensitivity to GABAergic inhibitory tone that has not been investigated in this study is the molecular AS pathology-in particular, the abnormal ubiquitination and degradation of Ube3a targets. For example, it recently was shown that Ube3a ubiquitinates proteins involved in GABA neurotransmission, such as the GABA transporter 1 (GAT 1 ) (Egawa et al., 2012) . Does Ube3a target the d-subunit of GABA A receptors? If so, deletion of Ube3a would lead to the accumulation of d-subunits and result in non-functional GABA A receptors. Future studies could be designed to address the molecular specificity of Ube3a targets, which if distinct for glutamatergic versus GABAergic neurons would confer cell specificity to the degradation process. Clearly, the identification of Ube3a targets is important for the identification of disease-relevant substrates that could be targeted for pharmacological interventions.
Despite the synaptic phenotypes, the Ube3a STOP/p+ ::Gad2-Cre mice do not display enhanced seizure susceptibility, EEG activity, or presynaptic accumulation of CCVs (Figure 1 ) (Judson et al., 2016) . Overall, these results suggest that a compromised ability of L2/3 pyramidal neurons to receive tonic GABA inhibition is not correlated with hyperexcitability and some of the pathological phenotypes described in AS mouse models. Decreases in tonic GABAergic neurotransmission could influence extracortical brain circuits and potentially alter the activity of neuronal networks. For instance, similar mechanisms of tonic inhibition mediated by d-GABA A Rs are present in other brain structures such as the hippocampus, striatum, thalamus, and cerebellum (Khazipov, 2016; Egawa et al., 2012; Huguenard and McCormick, 2007; Rektor et al., 2012) . In these brain structures, defective GABAergic tonic inhibition could cause an imbalance synchronization of activity in neuronal networks and generate abnormal brain activity patterns, a shifted temporal window for the integration of excitatory inputs, and impaired synaptic plasticity. Moving forward, it will be interesting to determine whether maternal deletion of Ube3a in either glutamatergic or GABergic neurons is involved in the generation of other AS behavioral phenotypes and whether this type of reductionist approach can delineate the specific neuronal circuits important for the generation of aberrant behaviors in AS.
